AZD4916

**AZD4916** is an orally administered investigational drug developed by AstraZeneca. It is currently being evaluated in a first-in-human Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. The drug is administered as an oral solution. As of now, the precise mechanism of action and therapeutic indication for AZD4916 have not been publicly disclosed. No efficacy or biological target data are available in the public domain. The development is in early clinical stages, and further information—including intended therapeutic area and molecular targets—remains undisclosed[1][2][4][5][7][9].